TTFA-Platin Conjugate: Deciphering the Therapeutic Roles of Combo-Prodrug through Evaluating Stability–Activity Relationship

This work introduces a novel Pt(II) based prodrug TTFA-Platin
that
integrates a β-diketonate ligand TTFA with a platinum scaffold
to structurally resemble carboplatin and offers intermediate kinetic
lability between cisplatin and carboplatin, striking a balance between
therapeutic efficacy and safety. A comprehensive stability and speciation
study was conducted in various biological media, mapping the therapeutic
effects of TTFA-Platin. A control molecule, TMK-Platin, was synthesized
to further validate the structural-stability relationship, which displayed
poor activatable features in biological systems. In vitro studies against a panel of cancer cell lines revealed that TTFA-Platin
exhibited significantly higher potency compared to TMK-Platin. In vivo studies revealed that TTFA-Platin exhibited significantly
lower toxicity than the reference platinum compounds. Thus, leveraging
ligands that fine-tune kinetic lability and offer therapeutic benefits
can help develop more effective and safer cancer treatments, addressing
the limitations of existing therapies.

本研究报道了一种新型铂(II)（Pt(II)）基前药TTFA-Platin，该药物将β-二酮配体（β-diketonate ligand）TTFA与铂骨架相结合，结构与卡铂（carboplatin）相似，其动力学不稳定性介于顺铂（cisplatin）与卡铂之间，实现了治疗疗效与安全性的良好平衡。研究团队在多种生物介质中开展了全面的稳定性与形态分布研究，以此明确TTFA-Platin的治疗效应。为进一步验证结构-稳定性相关性，研究人员同时合成了对照分子TMK-Platin，该分子在生物系统中表现出较差的可激活特性。针对一组癌细胞系开展的体外实验结果显示，TTFA-Platin的抗肿瘤活性显著高于TMK-Platin。体内实验则表明，TTFA-Platin的毒性显著低于参比铂类化合物。综上，通过配体精准调控动力学不稳定性并实现治疗获益，可为开发更高效、更安全的癌症治疗方案提供可行路径，以解决现有疗法的局限性。